Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers

Abstract The degradation of low-density lipoprotein receptor (LDLR) is induced by proprotein convertase subtilisin/kexin type 9 (PCSK9), resulting in elevated plasma concentrations of LDL cholesterol. Therefore, inhibiting the interactions between PCSK9 and LDLR is a desirable therapeutic goal for m...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Maryam Mahjoubin-Tehran, Samaneh Rezaei, Raul D. Santos, Tannaz Jamialahmadi, Wael Almahmeed, Amirhossein Sahebkar
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-05-01
Colecção:	Lipids in Health and Disease
Assuntos:	Aptamer PCSK9 LDLR LDL Hypercholesterolemia
Acesso em linha:	https://doi.org/10.1186/s12944-024-02151-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!